Home Institutions Mount Sinai clinical trials Institution Directory
Clinical trials at Mount Sinai Sites in New York, NY
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:33 PM EDT
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1098
Current sort
Recently updated
Campus scope
Mount Sinai, New York, NY
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 529–540 of 1,098 matching trials with a site at Mount Sinai, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.
Live official records
Conditions HIV Infection, Tobacco-Related Carcinoma
Interventions Computed Tomography, Smoking Cessation Intervention Procedure · Behavioral
Lead sponsor AIDS Malignancy Consortium Network
Eligibility 45 Years to 80 Years
Enrollment 100 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2023 – 2027
U.S. locations 11
States / cities La Jolla, California • Washington D.C., District of Columbia • Tampa, Florida + 7 more
Conditions Obstructive Hypertrophic Cardiomyopathy
Interventions Mavacamten, Non-mavacamten symptomatic oHCM therapy Drug
Lead sponsor Bristol-Myers Squibb Industry
Eligibility 18 Years and older
Enrollment 1,700 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2029
U.S. locations 60
States / cities Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more
Conditions Smoldering Plasma Cell Myeloma
Interventions Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration Biological · Drug · Other
Lead sponsor ECOG-ACRIN Cancer Research Group Network
Eligibility 18 Years and older
Enrollment 288 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2019 – 2029
U.S. locations 742
States / cities Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 490 more
Conditions New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions Anakinra, Tocilizumab, Standard medical treatment Drug · Other
Lead sponsor Yale University Other
Eligibility 2 Years and older
Enrollment 438 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2030
U.S. locations 25
States / cities Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
Conditions Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated With Down Syndrome, Myeloproliferative Neoplasm
Interventions Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine, Daunorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Thioguanine Drug · Other
Lead sponsor Children's Oncology Group Network
Eligibility 91 Days to 3 Years
Enrollment 280 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2015 – 2027
U.S. locations 169
States / cities Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 131 more
Conditions Genetic Disease
Interventions Genome Informed Risk Assessment (GIRA) report Other
Lead sponsor Vanderbilt University Medical Center Other
Eligibility 3 Years to 75 Years
Enrollment 26,877 participants
Healthy volunteers Accepts healthy volunteers
Timeline 2022 – 2030
U.S. locations 12
States / cities Birmingham, Alabama • Tempe, Arizona • Chicago, Illinois + 7 more
Conditions Sickle Cell Disease
Interventions Osivelotor Drug
Lead sponsor Pfizer Industry
Eligibility 12 Years and older
Enrollment 389 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2032
U.S. locations 46
States / cities Mobile, Alabama • Hartford, Connecticut • New Haven, Connecticut + 27 more
Conditions Obesity, Heart Failure
Interventions NNC0487-0111, Placebo Drug
Lead sponsor Novo Nordisk A/S Industry
Eligibility 18 Years and older
Enrollment 5,610 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2029
U.S. locations 206
States / cities Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 173 more
Conditions Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma (Prcc), Uterine Serous Carcinoma (USC), NSCLC (Non-small Cell Lung Cancer), Primary Peritoneal Cancer
Interventions SIM0505 for injection Drug
Lead sponsor NextCure, Inc. Industry
Eligibility 18 Years and older
Enrollment 738 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2028
U.S. locations 9
States / cities Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 6 more
Conditions Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Hematologic Malignancy, Refractory Hematologic Malignancy
Interventions Internet-Based Intervention, Best Practice, Telephone-Based Intervention, Questionnaire Administration, Post-intervention qualitative feedback interview Other
Lead sponsor Fred Hutchinson Cancer Center Other
Eligibility 18 Years and older
Enrollment 400 participants
Healthy volunteers Accepts healthy volunteers
Timeline 2025 – 2027
U.S. locations 4
States / cities Manhasset, New York • New York, New York • Seattle, Washington
Conditions Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA, Glomerulopathy, Immunoglobulin Disease
Interventions zigakibart Drug
Lead sponsor Novartis Pharmaceuticals Industry
Eligibility 18 Years to 100 Years
Enrollment 220 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2031
U.S. locations 8
States / cities Denver, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more
Conditions Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions Tolebrutinib, Placebo, Teriflunomide Drug
Lead sponsor Sanofi Industry
Eligibility 18 Years and older
Enrollment 2,500 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2029
U.S. locations 52
States / cities Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 47 more About this Mount Sinai institution page
What this page lists ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages , browse by condition , or browse by U.S. city .